Treating advanced melanoma: current insights and opportunities

References

• EricksonCDriscollMSMelanoma epidemic: facts and controversiesClin Dermatol201028328128620541680
   PubMed Web of Science ®Google Scholar
• TronnierMSemkovaKWollinaUTchernevGMalignant melanoma: epidemiologic aspects, diagnostic and therapeutic approachWien Med Wochenschr201316315–1635435823715934
   PubMedGoogle Scholar
• LinosESwetterSMCockburnMGColditzGAClarkeCAIncreasing burden of melanoma in the United StatesJ Invest Dermatol200912971666167419131946
   PubMed Web of Science ®Google Scholar
• GarbeCLeiterUMelanoma epidemiology and trendsClin Dermatol20092713919095149
   PubMed Web of Science ®Google Scholar
• VolkovovaKBilanicovaDBartonovaALetašiováSDusinskaMAssociations between environmental factors and incidence of cutaneous melanomaEnviron Health201211Suppl 1S1222759494
   PubMed Web of Science ®Google Scholar
• GarbeCPerisKHauschildAEuropean Dermatology ForumEuropean Association of Dermato-OncologyEuropean Organization of Research and Treatment of CancerDiagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline – Update 2012Eur J Cancer201248152375239022981501
   PubMed Web of Science ®Google Scholar
• ShtivelmanEDaviesMQHwuPPathways and therapeutic targets in melanomaOncotarget2014571701175224743024
   PubMed Web of Science ®Google Scholar
• AckermanABMalignant melanoma. A unifying conceptAm J Dermatopathol1980243093137468933
   PubMedGoogle Scholar
• MarVJWongSQLiJBRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damageClin Cancer Res201319174589459823833303
   PubMed Web of Science ®Google Scholar
• PoulikakosPIZhangCBollaqGShokatKMRosenNRAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAFNature2010464728742743020179705
   PubMed Web of Science ®Google Scholar
• LangGVMenziesAMNagrialAMPrognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanomaJ Clin Oncol201129101239124621343559
   PubMed Web of Science ®Google Scholar
• LongGVWilmottJSCapperDImmunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanomaAm J Surg Pathol2013371616523026937
   PubMed Web of Science ®Google Scholar
• ColombaEHélias-RodzewiczZvon DeimlingADetection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencingJ Mol Diagn20131519410023159108
   PubMed Web of Science ®Google Scholar
• IhleMAFassunkeJKönigKComparison of high resolution melting analysis, pyrosequenzing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E mutationsBMC Cancer2014141324410877
   PubMed Web of Science ®Google Scholar
• Saint-JeanMQuéreuxGNguyenJMIs a single BRAF wild-type test sufficient to exclude melanoma patients from vemurafenib therapy?J Invest Dermatol201413451468147024025553
   PubMed Web of Science ®Google Scholar
• EisenTAhmadTFlahertyKTSorafenib in advanced melanoma: a phase II randomised discontinuation trial analysisBr J Cancer200695558158616880785
   PubMed Web of Science ®Google Scholar
• FlahertyKTPuzanovIKimKBInhibition of mutated, activated BRAF in metastatic melanomaN Engl J Med2010363980981920818844
   PubMed Web of Science ®Google Scholar
• ChapmanPBHauschildARobertCBRIM-3 Study GroupImproved survival with vemurafenib in melanoma with BRAF V600E mutationN Engl J Med2011364262507251621639808
   PubMed Web of Science ®Google Scholar
• SosmanJAKimKBSchuchterLSurvival in BRAF V600-mutated advanced melanoma treated with vemurafenibN Engl J Med2012366870771422356324
   PubMed Web of Science ®Google Scholar
• GöppnerDMüllerJKrügerSFrankeIGollnickHQuistSRHigh Incidence of Naevi-associated BRAF Wild-type Melanoma and Dysplastic Naevi under Treatment with the Class I BRAF Inhibitor VemurafenibActa Derm Venereol Epub2142014
   Web of Science ®Google Scholar
• Perier-MuzetMThomasLPoulalhonNMelanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopyJ Invest Dermatol201413451351135824304815
   PubMed Web of Science ®Google Scholar
• ArgenzianoGLallasALongoCMoscarellaERaucciMZalaudekIDormant melanomas or changing nevi?J Invest Dermatol201413451196119824732333
   PubMed Web of Science ®Google Scholar
• TronnierMSmolleJWolffHHUltraviolet irradiation induces acute changes in melanocytic neviJ Invest Dermatol199510444754787706761
   PubMed Web of Science ®Google Scholar
• HauschildAGrobJJDemidovLVDabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialLancet2012380983935836522735384
   PubMed Web of Science ®Google Scholar
• MenziesAMLongGVRecent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyondEur J Cancer201349153229324123870385
   PubMed Web of Science ®Google Scholar
• DummerRRobertCNyakasMInitial results from a phase I, open-label, does escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metatastic melanomaJ Clin Oncol201331Suppl 15 abstract 9028
   Google Scholar
• Das ThakurMSalangsangFLandmanASModelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistanceNature2013494743625125523302800
   PubMed Web of Science ®Google Scholar
• JarkowskiA3rdKhushalaniNIBRAF and beyond: Tailoring strategies for the individual melanoma patientJ Carcinog201413124737949
   PubMedGoogle Scholar
• FlahertyKTRobertCHerseyPMETRIC Study GroupImproved survival with MEK inhibition in BRAF-mutated melanomaN Engl J Med2012367210711422663011
   PubMed Web of Science ®Google Scholar
• AdjeiAACohenRBFranklinWPhase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancersJ Clin Oncol200826132139214618390968
   PubMed Web of Science ®Google Scholar
• AsciertoPABerkingCAgarwalaEfficacy and safety of the oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutationsJ Clin Oncol201230Suppl abstract 8511
   Google Scholar
• FlahertyKTInfanteJRDaudACombined BRAF and MEK inhibition in melanomas with BRAF V600 mutationsN Engl J Med2012367181694170323020132
   PubMed Web of Science ®Google Scholar
• JakobJABassettRLJrNgCSNRAS mutation status is an independent prognostic factor in metastatic melanomaCancer2012118164014402322180178
   PubMed Web of Science ®Google Scholar
• WoodmanSEDaviesMATargeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeuticsBiochem Pharmacol201080556857420457136
   PubMed Web of Science ®Google Scholar
• Torres-CabalaCAWangWLTrentJCorrelation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acrallentiginous/mucosal typeMod Pathol200922111446145619718013
   PubMed Web of Science ®Google Scholar
• MinorDRKashani-SabetMGarridoMO’DaySJHamidOBastianBCSunitinib therapy for melanoma patients with KIT mutationsClin Cancer Res20121851457146322261812
   PubMed Web of Science ®Google Scholar
• HodiFSCorlessCLGiobbie-HurderAImatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skinJ Clin Oncol201331263182319023775962
   PubMed Web of Science ®Google Scholar
• BlanchardTSrivastavaPKDuanFVaccines against advanced melanomaClin Dermatol201331217919023438381
   PubMed Web of Science ®Google Scholar
• ChambersCAKuhnsMSEgenJGAllisonJPCTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapyAnnu Rev Immunol20011956559411244047
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• MargolinKErnstoffMSHamidOIpilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trialLancet Oncol201213545946522456429
   PubMed Web of Science ®Google Scholar
• YuanJAdamowMGinsbergBAIntegrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumabProc Natl Acad Sci U S A201110840167231672821933959
   PubMed Web of Science ®Google Scholar
• RobertCThomasLBondarenkoIIpilimumab plus dacarbazine for previously untreated metastatic melanomaN Engl J Med2011364262517252621639810
   PubMed Web of Science ®Google Scholar
• AsciertoPASimeoneEGiannarelliDGrimaldiAMRomanoAMozzilloNSequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical useJ Translat Med201210107
   PubMed Web of Science ®Google Scholar
• IwaiYIshidaMTanakaYOkazakiTHonjoTMinatoNInvolvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockadeProc Natl Acad Sci U S A20029919112931229712151601
   PubMed Web of Science ®Google Scholar
• TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med2012366262443245422658127
   PubMed Web of Science ®Google Scholar
• GrossoJHorakCEInzunzaDKeck School of Medicine of the University of Southern California, Los Angeles, CA; Dako North America, Inc., Carpinteria, CA. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO4538)J Clin Oncol201331Suppl abstract 3016
   Google Scholar
• HamidORobertCDaudASafety and tumor responses with lambrolizumab (anti-PD-1) in melanomaN Engl J Med2013369213414423724846
   PubMed Web of Science ®Google Scholar
• BrahmerJRTykodiSSChowLQSafety and activity of anti-PD-L1 antibody in patients with advanced cancerN Engl J Med2012366262455246522658128
   PubMed Web of Science ®Google Scholar
• HamidOSosmanJALawrenceDPClinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM)J Clin Oncol201331Suppl abstract 9010
   PubMed Web of Science ®Google Scholar
• HerseyPGallagherSIntralesional immunotherapy for melanomaJ Surg Oncol2014109432032624301265
   PubMed Web of Science ®Google Scholar
• MortonDLEilberFRHolmesECBCG immunotherapy of malignant melanoma: summary of a seven-year experienceAnn Surg197418046356434412271
   PubMed Web of Science ®Google Scholar
• DranoffGGM-CSF-secreting melanoma vaccinesOncogene200322203188319212789295
   PubMed Web of Science ®Google Scholar
• von WussowPBlockBHartmannFDeicherHIntralesional interferon-alpha therapy in advanced malignant melanomaCancer1988616107110743342367
   PubMed Web of Science ®Google Scholar
• Temple-OberleCFByersBAHurdleVFyfeAMcKinnonJGIntra-lesional interleukin-2 therapy for in transit melanomaJ Surg Oncol2014109432733124453036
   PubMed Web of Science ®Google Scholar
• DoukasJRollandAMechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanomaCancer Gene Ther2012191281181723037806
   PubMed Web of Science ®Google Scholar
• RussellSJPengKWBellJCOncolytic virotherapyNat Biotechnol201230765867022781695
   PubMed Web of Science ®Google Scholar
• AndtbackaRHICollichioFAAmatrudaTDepartment of Biostatistics and Epidemiology; Amgen, Inc.; Rush University Medical CenterOPTiM: A randomized phase III trial of talimogene laherparepvec (T-Vec) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanomaJ Clin Oncol201331Suppl abstract LBA9008
   PubMed Web of Science ®Google Scholar
• SrivastavaNMcDermottDUpdate on benefit of immunotherapy and targeted therapy in melanoma: the changing landscapeCancer Manag Res2014627928925018651
   PubMed Web of Science ®Google Scholar
• SlominskiATCarlsonJAMelanoma resistance: a bright future for academicians and a challenge for patient advocatesMayo Clin Proc201489442943324684870
   PubMed Web of Science ®Google Scholar
• DavarDTarhiniAAKirkwoodJMAdjuvant immunotherapy of melanoma and development of new approaches using neoadjuvant approachClin Dermatol201331323725023608443
   PubMed Web of Science ®Google Scholar